Invicta Diagnostic Limited

Medical/Nursing Services/ NSE

Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target

INVICTA

FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹68 today

BEAR

₹134

+97%

17.3% a year · 29.3x exit

BASE

₹183

+168%

30% a year · 36x exit

BULL

₹281

+313%

40.8% a year · 51.1x exit

Where the market has priced it

23x17x today — outside the range54x

this company has too little filed history for a multiple band of its own, so the exit multiple is the median of 7 Medical/Nursing Services peers
at 17x its FY26 earnings the stock trades below the bottom of its own ten-year range (29x)
the range is unusually wide — read it as the span of management's own claim, not as a forecast

How these numbers are produced

Earnings base	FY26 fiscal year EPS ₹3.91 (screener)
Guided growth	30% a year, said on the call of 25-May-2026 · transcript
Read across as	operating: unlabelled growth figure, read as revenue — medium confidence
Delivery calibration	0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple	29.27x / 36x / 51.12x, this company’s own p20 / median / p80 across 7 filed years
Filed-industry peers	median 36x across 7 peers — the cross-check, not the input
Arithmetic	base EPS × (1 + guided growth × delivery)¹ × exit multiple

Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

How to read this

It answers one question. If this management delivers the growth it told its own investors it would, and the market pays what it has historically paid for this company's earnings, where does the arithmetic land? Nothing here is a forecast of the share price.
Three cases, two moving parts. Bear, base and bull vary the delivery — what fraction of guidance managements actually file — and the exit multiple together, because a company that misses its guidance is usually de-rated for missing it. Each case shows the growth rate and the multiple that produced it.
Read the width, not just the middle. A wide gap between bear and bull means the inputs are uncertain, not that the upside is bigger. A narrow range is a more confident statement than a high one.
“Where the market has priced it” puts today's P/E on the company's own historical range. Sitting far below that range is why a scenario can look enormous: the number is then mostly about re-rating, not about delivery, and the board marks those separately.
The bullets underneath are the caveats — a borrowed peer multiple, a thin filed history, an earnings base that carried a one-off. They are the reasons to trust the number less, listed rather than buried.

Not a price target, not a recommendation, and not a forecast of what the stock will do. The field guide covers the method.

What management said

from NSE earnings-call filings · extracted, not interpreted

generic growth 30%

From FY26 to FY27, 30% CAGR growth, we are targeting with this IPO money.

Call 25-May-2026 · bridge confidence medium · transcript PDF

Coverage

SectorMedical/Nursing Services

Dossiersnone

Guidanceyes

Scenarioyes

Street chatter

unverified · logged from public channels

Invicta Diagnostic Limited Reports FY26 Total Income of ₹33.04 Cr with EBITDA Margins Above 30%

19 May 12:22

Invicta Diagnostic Limited Starts Commercial Operations at Pune Centre; Total Network Reaches 10 Diagnostic Centres

Mention only02 Jul 08:19

ectors: Infrastructure, Healthcare, and Specialty Chemicals appear to be gaining traction, indicated by positive gaps in SUPREMEINF, INVICTA, and HECPROJECT. There's also notable activity in the manufacturing and industrial machinery space (KCPSUGIND, RAJOOENG).

Commentary21 Jul 03:38